Lastacaft FDA Approval History
FDA Approved: Yes (First approved July 28, 2010)
Brand name: Lastacaft
Generic name: alcaftadine
Dosage form: Ophthalmic Solution
Company: Allergan plc
Treatment for: Conjunctivitis, Allergic
Lastacaft (alcaftadine ophthalmic solution) is a topical H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis.
Development Timeline for Lastacaft
| Date | Article |
|---|---|
| Jul 28, 2010 | ApprovalFDA Approves Lastacaft (alcaftadine ophthalmic solution) for Prevention of Itching Associated with Allergic Conjunctivitis |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
